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Abstract: Chemoprevention that impedes one or more steps in carcinogenesis, via long-term 
administration of naturally occurring or synthetic compounds, is widely considered to be a crucial 
strategy for cancer control. Selenium (Se) has chemopreventive effects, but its application is 
limited due to a low therapeutic index as shown in numerous animal experiments. In contrast to 
Se, which was known for its toxicity prior to the discovery of its beneficial effects, the natural 
compound epigallocatechin-3-gallate (EGCG) was originally considered to be nontoxic. Due 
to its preventive effects on many types of cancer in various animal models, EGCG has been 
regarded as a prime example of a promising chemopreventive agent without major toxicity 
concerns. However, very recently, evidence has accumulated showing that efficacious doses of 
EGCG used in health promotion may not be far from its toxic dose level. Therefore, both Se and 
EGCG need to be modified by novel pharmaceutical technologies to attain enhanced efficacy 
and/or reduced toxicity. Nanotechnology may be one of these technologies. In support of this 
hypothesis, the characteristics of polylactic acid and polyethylene glycol-encapsulated nano-
EGCG and elemental Se nanoparticles dispersed by bovine serum albumin are reviewed in this 
article. Encapsulation of EGCG to form nano-EGCG leads to its enhanced stability in plasma 
and remarkably superior chemopreventive effects, with more than tenfold dose advantages in 
inducing apoptosis and inhibition of both angiogenesis and tumor growth. Se at nanoparticle 
size (“Nano-Se”), compared with Se compounds commonly used in dietary supplements, has 
significantly lower toxicity, without compromising its ability to upregulate selenoenzymes at 
nutritional levels and induce phase II enzymes at supranutritional levels.
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Chemoprevention
Chemoprevention is defined as the use of compounds to inhibit the development 
of cancer, either by blocking the DNA damage that initiates carcinogenesis or by 
arresting or reversing the progression of premalignant cells in which such damage has 
already occurred.1 The expanded definition of chemoprevention is: through the use 
of natural or synthetic substances, to reverse, suppress, and prevent either the initial 
phase of carcinogenesis or the progression of neoplastic cells to cancer.2 Among many 
diverse chemopreventive agents, epigallocatechin-3-gallate (EGCG) and various forms 
of selenium (Se) have been extensively investigated.3,4
EGCG
Tea is one of the most widely consumed beverages worldwide. Green tea contains 
large quantities of biologically active catechins, which have been identified as 
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important dietary factors for health promotion over the past 
two decades.5 Among the six kinds of catechins in green 
tea, EGCG accounts for half or more of total catechin in 
green tea.6
Efficacious and toxic doses of EGCG
The chemopreventive effects of EGCG have been confirmed 
in at least 13 human or animal organs, including the 
esophagus, stomach, lung, small intestine, large intestine, 
colon, skin, liver, bladder, prostate, pancreas, mammary 
glands, and oral cavity.7 Most of the studies used the regimen 
of adding EGCG or green tea extract with EGCG as the 
major component to drinking water.8–13 As a prominent 
chemopreventive agent, EGCG must be amenable to 
prolonged ingestion at levels in excess of normal dietary 
intake without inducing adverse effects. Because the potential 
toxicity related to such a regimen has not been investigated, 
it remains uncertain whether the efficacious doses for 
chemoprevention are really as far away from the toxic doses 
as have been superficially inferred.
However, EGCG administration via diet or intraperitoneal 
(IP) injection has been reported to be associated with 
various adverse effects. Mice consuming a diet with 1% 
EGCG for 6 weeks exhibited elevated splenocyte and 
macrophage proinflammatory markers such as tumor 
necrosis factor-α, interleukin-6, interleukin-1β, and 
prostaglandin E2 and disturbed immune cell populations.14 
A single IP administration of 100 mg/kg EGCG to mice 
can generate hepatotoxicity, whereas 150 mg/kg results in 
100% mortality within 24 hours.15 Furthermore, a causal 
association between the consumption of green tea extract 
and liver damage has recently been established in humans.16 
Thirty-four cases of hepatitis following the consumption 
of green tea extract for the purpose of obesity control have 
been documented.16 Upon liver histological examination, 
inflammatory reactions, cholestasis, steatosis, and necrosis 
were noted. A positive dechallenge was reported in 29 cases, 
and a positive rechallenge occurred in seven cases.16 The 
mechanism of EGCG toxicity has been ascribed to its 
pro-oxidant action, because oxidative stress-associated 
biomarkers, including hepatic malonyldialdehyde, 
4-hydroxynonenal, metallothionein, and phosphorylated 
histone 2AX, substantially increase in EGCG-intoxicated 
mice.17 Tea can contain pesticide residues that might 
cause adverse effects, including hepatotoxicity. Therefore, 
some cases of tea-related hepatotoxicity may be ascribed 
to the presence of pesticide residues in tea. However, the 
published data showing that EGCG is able to cause adverse 
effects in experimental animals were obtained by using 
purified EGCG.
In addition to its cancer-preventive effect, EGCG has 
potential in the prevention of obesity, diabetes, and neurode-
generative diseases. Herein we listed some literature-reported 
beneficial doses administered through diet or the IP route 
to obtain a window concept of efficacious doses and toxic 
doses (Table 1). In the studies involving cancer, 0.5%–1% 
EGCG in the diet was used for 7–24 weeks;18,19 50–60 mg/kg 
EGCG was IP administered for 2–23 weeks.20,21 In the studies 
involving type 2 diabetes mellitus and obesity, 0.32%–1% 
EGCG in the diet was used for 4–16 weeks.22–25 In the studies 
involving liver and brain protection, 50–75 mg/kg EGCG was 
IP administered for 1–56 days.14,26,27 Based on the evidence 
that both 1% EGCG in the diet for 6 weeks of administration 
and a single IP injection of 100 mg/kg EGCG have adverse 
effects on mice, it seems obvious that the efficacious doses 
of EGCG including chemopreventive doses are not far from 
Table 1 Efficacious doses and toxic doses of epigallocatechin-3-gallate in mice
Delivery route Times of administration Outcomes References
0.32% in diet 16 weeks Inhibiting obesity and fatty liver 23,24
0.5% in diet 7 weeks Inhibiting tumor development 18
1% in diet 24 weeks Not inhibiting B(α)P-promoted tumorigenesis 19
1% in diet 7 weeks Alleviating type 2 diabetes mellitus 25
1% in diet 4 weeks Inhibiting obesity 22,24
1% in diet 6 weeks Proinflammatory responses 14
IP 50 mg/kg 2 weeks Reducing angiogenesis 20
IP 50 mg/kg 1 day Reducing brain damage 26
IP 50 mg/kg 8 weeks Reducing liver fibrosis 27
IP 60 mg/kg 23 weeks Inhibiting 1,2-DMH-promoted tumorigenesis 21
IP 50–75 mg/kg 3 days Preventing acute hepatotoxicity 14
IP 100 mg/kg 1 day Hepatotoxicity 15
IP 150 mg/kg 1 day Died within 24 hours 15
Abbreviations: 1,2-DMH, 1,2-dimethylhydrazine; B(α)P, benzo(α)pyrne; IP, intraperitoneal.
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its toxic dose levels; furthermore, some efficacious doses 
actually overlap with the toxic doses.
Intervention time of EGCG  
in chemoprevention
In addition to the aforementioned dose concerns, results 
obtained regarding the optimal intervention time for EGCG 
chemoprevention are not particularly promising either. In a 
transgenic adenocarcinoma of the mouse prostate (TRAMP) 
model, which closely emulates human disease, it was found 
that an intervention starting at the age of 8 weeks by adding 
green tea polyphenol (GTP), with EGCG as the major 
component to drinking water at a concentration of 0.1% 
(w/v), generated pronounced chemopreventive efficacy.28 
Specifically, the GTP treatment reduced the cancer incidence 
in TRAMP mice from 100% to 35% and the cancer metastasis 
to lymph and liver to null from 95% and 65%, respectively. 
Without the GTP treatment, the TRAMP mice had enlarged 
prostate and genitourinary weight (4.6- and 8.3-fold compared 
with the nontransgenic mice, respectively), whereas the GTP 
treatment decreased prostate and genitourinary hyperplasia 
by 64% and 72%, respectively. The GTP treatment 
significantly increased median life expectancy of TRAMP 
mice from 42 weeks to 68 weeks. In the serum of TRAMP 
mice, elevated insulin-like growth factor-1 and vascular 
endothelial growth factor were significantly reversed by 
the GTP treatment. In the prostate tissue of TRAMP mice, 
several key proliferation-associated signaling proteins and 
metastasis-related proteins were substantially suppressed 
by the GTP treatment.28,29 These impressive experimental 
results suggest that GTP or EGCG has tremendous potential 
for prostate cancer prevention.
The impact of GTP intervention time on prostate cancer 
prevention in TRAMP mice was further investigated by 
the same team. Significantly, unlike the promising results 
obtained when GTP was initiated at the age of 8 weeks, when 
treatment started at 18 weeks the preventive effect was largely 
compromised, whereas when begun at the age of 28 weeks 
the preventive effect disappeared almost completely.30 The 
median life span of TRAMP mice is 42 weeks. Given that the 
human median life span is 70 years, accordingly (if the effect 
in humans was analogous), someone starting to drink green 
tea at 13 years old (equivalent to the 8th week of TRAMP 
mice) might gain a pronounced chemopreventive effect, 
whereas starting at 30 years old (equivalent to the 18th week 
of TRAMP mice) might have only a weak effect on cancer 
development. Thus, the promising chemopreventive effects 
of GTP might be largely limited to earlier intervention for 
adolescents, who nowadays prefer carbonated drinks rather 
than tea in many parts of the world. For adults who are willing 
to accept chemopreventive practices, the chemopreventive 
efficacy of EGCG needs to be enhanced.
Encapsulated nano-EGCG  
for chemoprevention
Typically, but not exclusively, nanoscience investigates objects 
in the range of 1–100 nm.31 As applied to biology, this field 
has led to the advent of nanomedicine, which has many facets, 
one of the most important of which is the nanofabrication 
of drugs in nanoparticle-based drug-delivery systems.32–34 
One advantage of this technology is that drugs included in 
nanoformulations can be protected from the destructive action 
of external media.35 In addition, it is now well established 
that drugs encapsulated in nanoparticles exhibit distinct 
pharmacokinetic and pharmacodynamic profiles as compared 
with the nonencapsulated free drugs.36,37
“Nanochemoprevention”, a term coined by Siddiqui 
and Mukhtar38 very recently, involves the utilization of 
nanotechnology to improve the pharmacokinetic and 
pharmacodynamic profiles of chemopreventive agents. For 
example, curcumin is a widely studied phytochemical with 
chemopreventive potential. Encapsulated nanocurcumin 
manifests enhanced cellular uptake and cytotoxicity in vitro, 
as well as superior bioavailability and anticancer activity 
in vivo over nonencapsulated free curcumin.39–41 EGCG 
encapsulated in lipid nanocapsules exhibited a stable status 
without degradation in the aqueous phase over 4 weeks, 
whereas free EGCG totally degraded within 4 hours.42 
When EGCG is encapsulated in chitosan, its bioavailability 
significantly increases compared with nonencapsulated 
free EGCG. Specifically, oral administration of chitosan-
encapsulated nano-EGCG enhanced intestinal absorption 
by a factor of 1.8 relative to free EGCG and enhanced the 
plasma exposure of total EGCG by a factor of 1.5 relative to 
free EGCG.43,44 Polylactic acid (PLA) and polyethylene glycol 
(PEG) are biologically inert and completely biocompatible 
without toxicity or antigenic reactions.45 EGCG can be 
encapsulated in PLA–PEG nanoparticles46 whose average 
size is 260 nm, as shown in supplementary figure S1–2 
in Siddiqui et al.46 The biological activities of PLA–PEG-
encapsulated nano-EGCG versus nonencapsulated free 
EGCG have been compared in term of apoptosis induction, 
inhibition of angiogenesis and tumor growth, and EGCG 
retention in blood after IP administration, as summarized 
in Table 2.46 Overall, PLA–PEG-encapsulated nano-EGCG, 
compared with the nonencapsulated free EGCG, is resistant 
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to degradation in blood and produces remarkably superior 
chemopreventive effects, with an over tenfold dose advantage 
in inducing apoptosis and inhibiting angiogenesis and tumor 
growth. Together, these studies reveal that nanoparticle-
mediated delivery of EGCG could serve as a basis for 
enhancing the bioavailability of EGCG.
Selenium
Although phytochemicals including EGCG have received 
considerable attention for their cancer-preventive effects, the 
most extensively investigated chemopreventive agent is Se, 
as indicated in Figure 1, which depicts the search results for 
the number of papers in PubMed using the keywords “cancer 
prevention” or “chemoprevention” along with the specific 
chemopreventive agent.
Se-dependent selenoproteins  
and cancer prevention
Se is capable of exerting multiple actions on the physiological 
system  by  modifying  the  expression  of  25  human 
selenoproteins, whose synthesis is dependent upon the 
incorporation of the 21st genetically encoded protein amino 
acid, selenocysteine.47–49 Most of the selenoproteins, such 
as selenoenzymes of glutathione peroxidases (GPx) and 
thioredoxin reductases (TrxR), take part in antioxidant 
defense.50–52 Activities of seleoenzymes are affected by 
Se at nutritional levels; therefore, Se deficiency leads to 
reduced activities of seleoenzymes.53,54 Transgenic mice 
whose selenoprotein synthesis is disrupted are predisposed 
to precancerous changes.55,56 Human epidemiological studies 
have found an inverse relationship between Se status and 
cancer risk.4,57 In SELECT (the Selenium and Vitamin E 
Cancer Prevention Trial), the participants had optimal Se 
status; thus, Se supplementation at nutritional level had no 
effect on cancer risk, whereas the participants with low Se 
status showed reduced cancer risk after Se supplementation 
at nutritional levels.58,59 These results suggest that Se at 
nutritional levels has a cancer-prevention effect via enhancing 
the expression of selenoproteins in those subjects with 
suboptimal Se status.
Se-induced phase II enzymes  
in cancer prevention
Phase II enzymes such as quinone reductase and glutathione 
S-transferase (GST) are a class of inducible enzymes that are 
upregulated in response to toxic insults.60 Upregulation of 
phase II enzymes has been implicated in the detoxification 
Table  2  Comparison  of  biological  activities  between  encapsulated  nanoepigallocatechin-3-gallate  (EGCG)  and  nonencapsulated 
free EGCG
Biomarkers Encapsulated nano-EGCG Nonencapsulated free EGCG
IC50 of PCa PC3 cells 3.74 μmol/L 43.6 μmol/L
Doses needed to generate 72% apoptosis in PCa PC3 cells 2.7 μmol/L 40 μmol/L
Inhibiting colonies formation of PCa PC3 cells 5.5 μmol/L inhibited 90% 20 μmol/L inhibited 10%
Bax/Bcl-2 ratio of PCa PC3 cells 2 at 1.4 μmol/L 0.5 at 20 μmol/L
Inhibition of FGF-promoted angiogenesis in vitro 3 μg/CAM generated 57% inhibition 30 μg/CAM generated 35% 
inhibition
Suppressing tumor growth in mice inoculated with androgen- 
responsive 22Rν1 cells after 7 weeks of EGCG administration
IP 0.1 mg/mouse inhibited 50% as compared  
with tumor control
IP 1 mg/mouse inhibited 50% as 
compared with tumor control
Serum PSA of mice inoculated with androgen-responsive  
22Rν cells after 7 weeks of EGCG administration
10% of tumor control/IP 0.1 mg/mouse 75% of tumor control/ 
IP 1 mg/mouse
EGCG degradation in plasma of mice EGCG existed in plasma after 4 hours/ 
IP 0.1 mg/mouse
EGCG disappeared from plasma 
after 4 hours/IP 1 mg/mouse
Abbreviations: CAM, chick chorioallantoic membrane; FGF, fibroblast growth factor; IC50, the half maximal inhibitory concentration; IP, intraperitoneal; PCa, prostate cancer; 
PSA, prostate-specific antigen.
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of numerous oxidative and electrophilic species during 
xenobiotic metabolism.61 The cancer-preventive effect 
of many chemopreventive agents, including EGCG, 
sulforaphane, curcumin, and resveratrol, is associated 
with the upregulation of phase II enzymes.62–66 Among 
various phase II enzymes, GST plays an important role 
in cellular protection against carcinogens by conjugating 
their electrophilic metabolites with GSH.67,68 Evidence 
suggests that the level of GST expression is a crucial 
factor in determining the sensitivity of cells to a broad 
spectrum of toxic chemicals; hence, the induction of GST 
by chemopreventive agents enables experimental animals to 
tolerate exposure to carcinogens.69 Enhanced GST expression 
can limit tumor development.70 Many Se compounds can 
oxidize thiols, consequently producing superoxide and other 
reactive oxygen species (ROS).71,72 Modest amounts of ROS 
promote the translocation of the transcription factor Nrf2 into 
the nucleus, where Nrf2 binds to the antioxidant response 
element in phase II enzyme genes to activate the transcription 
of phase II enzyme mRNAs.73 Xiao and Parkin74 found that 
16 Se compounds were able to increase quinone reductase 
activity, and seven of them also increased GST activity in 
murine hepatoma cells. Se at supranutritional levels, which 
are roughly ten- to 30-fold higher than nutritional levels, is 
capable of inducing phase II enzymes and exhibits powerful 
chemopreventive effects.75–79 Thus, the chemopreventive 
effects of Se at supranutritional levels are associated with 
the induction of phase II enzymes.
Se-mediated cytotoxicity  
and cancer prevention
The ROS that originate from Se-promoted thiol   oxidation, if in 
sufficient quantity, will result in intracellular and extracellular 
oxidative stress, leading to cytotoxicity.80,81 The cytotoxic 
effects of Se may partially account for their chemopreventive 
activity.82–84 However, the general therapeutic utility of this 
mechanism is questionable and should be approached with 
caution. It is known that inhibition of TrxR results in enhanced 
selenite cytotoxicity and that cells overexpressing TrxR1 
are significantly more resistant to selenite cytotoxicity than 
control cells.85,86 TrxR1 has been shown to be upregulated in 
various cancer cells; thus, cancer cells are likely to be more 
resistant than normal cells to Se cytotoxicity. Drug-resistant 
tumor cells with high intracellular GSH exhibit a high degree 
of sensitivity to selenite cytotoxicity, whereas normal cells 
with high intracellular GSH would be more sensitive to 
Se cytotoxicity than some types of cancer cells with low 
intracellular GSH.87,88 Normal cells possess functional p53, 
which is mutated in most cancer cells. It has been shown 
that p53 can enhance the cytotoxicity of Se, suggesting that 
normal cells may be more sensitive to Se cytotoxicity than 
p53-mutated cancer cells.89–92 Indeed, the cytotoxic effects of 
both inorganic and organic Se compounds were more potent 
in normal hepatocytes as compared with hepatic carcinoma 
cells, and nontumorigenic prostate cells are highly sensitive 
to Se toxicity as compared with prostate cancer cells at 
physiologically relevant concentrations.93,94 For Se-induced 
cytotoxicity to be able to operate as a chemopreventive 
mechanism, Se toxicity would appear to be unavoidable. 
Therefore, Se-dependent selenoproteins and Se-induced 
phase II enzyme mechanisms, which are not associated with 
evoked toxicity, become more attractive to explain the cancer-
preventive effects of Se, whereas the “enhanced cytotoxicity” 
mechanism ought to be limited to Se-sensitive cancer cells 
whose proliferation can be effectively suppressed by Se at 
safe doses.
Preparation of elemental  
Se nanoparticles
A decade ago, elemental Se in the redox state of zero was 
considered to be biologically inert.95 Indeed, red elemental Se, 
formed in the redox system of selenite and GSH, is unstable 
and can further aggregate into gray or black elemental Se if 
there are no controlling factors in the redox system, leading 
to the disappearance of bioactivities.96 We reported in 2001 
that the presence of proteins such as bovine serum albumin 
(BSA) in the redox system at a tenfold excess by mass relative 
to Se can control the aggregation of elemental Se atoms; the 
resultant Se particles, referred to as Nano-Se, fall into a size 
distribution of 20–60 nm, with an average size of 36 nm.96 
Consistent with this finding, Mishra et al97 demonstrated 
the formation of BSA-dispersed Se nanoparticles when 
selenourea was oxidized into elemental Se. Dobias et al98 
recently showed that some particular proteins, such as alcohol 
dehydrogenase, can specifically bind to Se nanoparticles, 
resulting in a narrower size distribution. In addition to protein, 
polysaccharides have been revealed to be effective dispersants 
for controlling the formation of Se nanoparticles.99,100 The 
formation of Se nanoparticles is not limited to in vitro 
conditions, as some strains of micro-organisms have the 
capacity of reducing selenite into Se nanoparticles.101–103
The bioactivities and toxicities of inorganic sodium sel-
enite, organic selenomethionine (SeMet), and Se-methylsele-
nocysteine (SeMSC) have been extensively investigated. 
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Based on the preceding review, the optimal form of Se for 
nutritional supplementation and cancer   prevention would 
be expected to have distinctly low toxicity and to possess 
good bioactivities in terms of upregulating selenoenzymes 
at nutritional levels and inducing phase II enzymes at supra-
nutritional levels.
Comparison of bioactivities and toxicities 
between inorganic Se and Nano-Se
Sodium selenite has been used in livestock and humans 
to prevent Se-deficiency disorders. Usually, it is used as a 
reference Se compound in the studies of Se bioavailability and 
toxicity. In HepG2 cells, although selenite dose-dependently 
increased GPx and PHGPx activities (R2 = 0.9881 and 
0.9956, respectively), there were no significant differences 
in elevating these selenoenzyme activities between selenite 
and Nano-Se at the same doses, based on total Se content.96 
When Nano-Se and selenite were added to a Se-deficient 
diet at a level of 0.1 ppm Se for Se supplementation in rats, 
selenite significantly increased hepatic Se by 8.8-fold and 
hepatic GPx activity by 48.8-fold. There were no significant 
differences in these biomarkers between selenite and 
Nano-Se.96 These in vitro and in vivo results demonstrate that 
the bioavailability of the two Se sources is equal.
Selenite toxicity is associated with the interaction of 
selenite with GSH to form reactive selenotrisulfides, leading 
to the production of ROS.80 Selenite is one order of magnitude 
more effective than Nano-Se in oxidizing GSH, suggesting 
that the cytotoxic effect of selenite but not Nano-Se may 
be enhanced by extracellular GSH.96 Indeed, exposure of 
HepG2 cells to the cotreatment of nontoxic Nano-Se and GSH 
reveals no cytotoxicity, whereas exposure of HepG2 cells to 
the cotreatment of an otherwise nontoxic dose of selenite, but 
in the presence of GSH, produced significant cytotoxicity.96 
According to this evidence, it is anticipated that in tissues 
where extracellular GSH is elevated, enhanced cytotoxicity will 
be much more likely to occur for selenite than for Nano-Se. 
Consequently, selenite would be more toxic than Nano-Se 
in vivo. Indeed, the oral acute toxicity of selenite was 7.2-fold 
that of Nano-Se, according to the medium lethal dose (LD50) 
values obtained from mice.96 The US National Research 
Council recommends growth inhibition as the best indicator of 
Se toxicity.104 The major target of Se toxicity is liver tissue.105 
In a short-term toxicity study, mice were orally administered 
saline as control, Nano-Se, and selenite at 4 mg Se/kg for 
4 weeks. Body weight in the selenite group was significantly 
suppressed by 30%, whereas body weight in the Nano-Se 
group remained not significantly different from the control.106 
At the end of the experiments, selenite caused prominent liver 
injury, whereas the hepatic architecture in the Nano-Se group 
remained unaltered.106 Furthermore, in a subchronic toxicity 
study in which rats were fed with diets containing 0 ppm, 
2 ppm, 3 ppm, 4 ppm, and 5 ppm Se for 13 weeks, Nano-Se 
unequivocally manifested lower toxicity compared with either 
inorganic selenite or naturally occurring Se-enriched soy 
protein (high-Se protein) in all observed biomarkers, including 
growth inhibition, hematology, clinical chemistry, relative 
organ weights, and histopathology parameters (Table 3).107
Table 3 Subchronic toxicity of selenium (Se) compounds in rats
Biomarkers Se (ppm)  
in diet
Nano-Se Selenite High-Se 
protein
NOAEL (ppm) 3 2 2
Growth retardation 3 Nano-Se , selenite and high-Se protein
BWL 3 Nano-Se , selenite and high-Se protein
4 Nano-Se , selenite and high-Se protein
Reduction of erythrocyte, hemoglobin, platelet counts 4 Not significantly Significantly Significantly
Spleen enlargement and liver atrophy 3 Not significantly Not significantly Significantly
4 Not significantly Significantly Significantly
Mottled liver surface 4 Nano-Se , selenite and high-Se protein
5 Nano-Se , selenite and high-Se protein
Degeneration of liver cells 3 None Existence Existence
Patchy necrosis 5 None Existence Existence
Increase of ALT activity 4 Not significantly Significantly Not significantly
Increase of AST activity 4 Not significantly Significantly Not significantly
5 Not significantly Significantly Significantly
Increase of TP activity 5 Not significantly Significantly Significantly
Increase of ALB activity 5 Not significantly Significantly Significantly
Abbreviations: ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BWL, body weight loss; NOAEL, the no-observed-adverse-effect level; 
TP, total protein.
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Comparison of bioactivities and toxicities 
between organic Se and Nano-Se
SeMet is the predominant chemical form of Se in foodstuffs. 
Numerous experimental studies have suggested that SeMet 
has excellent bioavailability and lower toxicity, as compared 
with selenite.108 Because Nano-Se has lower toxicity profiles 
compared with the high-Se protein whose Se constitution 
would be largely taken up by SeMet, it is warranted to make 
direct and comprehensive comparisons between Nano-Se 
and SeMet in terms of bioactivities and toxicity.107 SeMet 
and Nano-Se were orally administered to Se-deficient 
mice daily for 7 days at two nutritional doses to compare 
bioavailability, and at a supranutritional dose to evaluate phase 
II enzyme induction. Although SeMet has been considered 
as a good Se source with excellent bioavailability, at the 
two tested nutritional doses, SeMet and Nano-Se equally 
increased tissue Se levels and the activities of GPx and TrxR.109 
  Significant differences between the two Se sources were found 
at the supranutritional dose; SeMet increased Se levels more 
efficiently than Nano-Se in all measured   tissues, including the 
liver, kidney, and blood.109 However, the high retention of Se in 
the liver subjected to SeMet did not   guarantee that SeMet could 
increase hepatic GST activity; in contrast, Nano-Se, which 
provided less Se to the liver compared with SeMet, generated 
a significant induction of hepatic GST compared with either 
the control group or the SeMet group.109 Se sequestration 
in protein via the nonspecific replacement of methionine 
using SeMet can readily explain such a paradoxical result.110 
Excess substitution of methionine residues by SeMet may 
alter physiochemical properties of some structural proteins 
and reduce the accumulation of active Se species that exert 
anticancer actions.110
Thus, the high Se accumulation deposited by SeMet at 
supranutritional levels cannot necessarily be considered as a 
merit; in contrast, it reduces the chemopreventive potential 
of SeMet, as evidenced by the GST induction, and increases 
the risk of SeMet toxicity. This interpretation is supported 
by the following results: (1) the acute oral toxicity of SeMet 
was 3.6-fold that of Nano-Se according to the LD50 values 
obtained from mice;109 (2) following administration of a single 
oral dose of 10 mg Se/kg to mice, after 12 hours, Nano-Se 
did not significantly elevate serum liver enzymes, but SeMet 
significantly increased serum alanine aminotransferase, aspar-
tate aminotransferase, and lactate dehydrogenase activities by 
fourfold to 25-fold relative to the control;109 and (3) following 
repetitive daily oral administration of 5 mg Se/kg/day to mice 
for 7 days, SeMet exhibited significantly higher toxicity than 
Nano-Se in terms of growth suppression and liver injury.109
SeMSC is considered to be one of the most effective 
Se compounds for chemoprevention, but unfortunately its 
systemic toxicities are high as well.112–114 Zhang et al111 
have demonstrated that SeMSC and Nano-Se have equal 
bioavailability at nutritional doses. Although the GST 
induction efficacy of the two Se sources was similar at 
supranutritional doses, SeMSC had a greater tendency toward 
Se toxicity.111 This is evidenced by: (1) the acute oral toxicity 
of SeMSC was 6.3-fold that of Nano-Se according to the LD50 
values obtained from mice;111 (2) following administration of a 
single oral dose of 10 mg Se/kg to mice, after 12 hours, serum 
alanine aminotransferase, aspartate aminotransferase, and 
lactate dehydrogenase activities were all significantly higher 
in SeMSC-treated mice than in Nano-Se-treated mice;111 and 
(3) following repetitive daily oral administration of 10 mg Se/
kg/day to mice for 7 days, SeMSC resulted in 80% mortality, 
whereas Nano-Se resulted in only 10% mortality.111
At supranutritional levels, Wang et al109 and Zhang et al111 
found that SeMSC, as with SeMet, increased Se levels more 
efficiently than Nano-Se in all measured tissues. High Se 
accumulation in SeMet-treated mice can be attributed to 
Se sequestration via nonspecific substitution of SeMet for 
methionine in proteins. Obviously, such a mechanism cannot 
apply in the case of high Se accumulation produced by 
supranutritional SeMSC; however, the significant differences 
in tissue Se retention between SeMSC and Nano-Se may be 
affected by the pore size of vessels. The pore sizes of normal 
vessels are 2–6 nm, so the entry of SeMSC molecules at 
approximately 1 nm appears not to be limited, whereas the 
entry of Se nanoparticles with an average size of 36 nm 
(20–60 nm) should be affected by vessel pore sizes. To 
support this hypothesis, ie, to observe the impact of size on Se 
accumulation, we prepared two kinds of Nano-Se with different 
size distributions, based on the principle that, during their 
preparation, a higher BSA concentration generates smaller Se 
nanoparticles.115,116 As expected, we found that Se accumulation 
at supranutritional levels was size dependent, such that small 
size led to high Se retention.116 It is worth noting that size-
dependent Se accumulation has an important implication in 
explaining the low toxicity of Nano-Se. Cells may change 
to passive absorption of Se at near-toxic supranutritional 
levels after the most fundamental physiological needs of a 
cell for selenoenzyme synthesis have been fully met. Under 
such conditions, large size would constitute a barrier for Se 
nanoparticles to enter into cells.117
Therefore, the significantly reduced Se accumulation in 
tissues subjected to Nano-Se at supranutritional levels as 
compared with SeMet or SeMSC may effectively prevent 
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Se toxicity.109,111 In addition, although Se nanoparticles show 
reduced Se retention in normal tissues as compared with 
SeMet and SeMSC, Se nanoparticles may show enhanced 
Se permeation and retention in tumor tissues, because tumor 
blood vessels possess large pores with a size distribution 
ranging from 100 nm to 800 nm, in stark contrast to small 
pores of 2–6 nm in the vessels of healthy tissues.118 This 
would confer a unique “targeting” advantage to Nano-Se, 
unavailable with other forms of Se. Recently, Sommer et al119 
demonstrated that pulsed red laser light can force cancer 
cells to take up cytotoxic drugs, including EGCG, via nano-
scopic interfacial water layers in cells, thereby resulting in 
enhanced cytotoxicity. Because nanoparticles have inherent 
characteristics of enhanced permeation and retention in tumor 
tissues,118 with the auxiliary effect of pulsed red laser light, 
the targeting advantage of Nano-Se and nano-EGCG would 
likely be further enhanced.
Conclusions and future prospectives
EGCG is a naturally occurring chemopreventive agent. 
PLA–PEG-encapsulated nano-EGCG, compared with 
nonencapsulated free EGCG, is resistant to degradation in blood 
and produces remarkably superior chemopreventive effects, 
with over a tenfold dose advantage in inducing apoptosis, 
inhibiting angiogenesis and tumor growth. So Nano-EGCG 
provides a paradigm for the use of nanoparticle-mediated 
delivery to enhance bioavailability. Se is a chemopreventive 
agent with a narrow margin between toxic amounts and the 
amounts needed for dietary requirements or therapeutic effects, 
ie, a low therapeutic ratio. Compared with selenite, SeMet, 
and SeMSC, Nano-Se has significantly lower toxicity, without 
compromising the important therapeutic capacities of increasing 
the activities of selenoenzymes and phase II enzymes. The 
safety margin and potential toxic effects of Se are important 
considerations for its role in supplementation. Therefore, 
Nano-Se can be considered as a novel chemoprevention agent 
with reduced risk of Se toxicity. Nanotechnology holds promise 
for chemoprevention, because anticancer nutrients fabricated 
at the nanometer scale exhibit drastically altered bioactivities 
and toxicity. Sustained exploration of the nanochemoprevention 
concept may lead to exciting new horizons in the discovery 
of novel chemopreventive agents, with an expanded window 
between efficacious doses and toxic doses.
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